Mesa Laboratories Inc (MLAB)

Currency in USD
106.04
-7.16(-6.33%)
Closed·
106.040.00(0.00%)
·
MLAB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
105.24115.43
52 wk Range
58.83115.52
Key Statistics
Prev. Close
113.2
Open
113.09
Day's Range
105.24-115.43
52 wk Range
58.83-115.52
Volume
161.03K
Average Volume (3m)
201.19K
1-Year Change
53.9713%
Book Value / Share
34.17
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MLAB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
117.50
Upside
+10.81%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth

Mesa Laboratories Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

1 Buy
2 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 117.50
(+10.81% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Wells Fargo
Hold110.00+3.73%94.00Maintain14/08/2026
Jefferies
Buy130.00+22.60%115.00Maintain29/05/2026
Wells Fargo
Hold94.00-11.35%83.00Maintain04/02/2026
Wells Fargo
Hold83.00-21.73%75.00Maintain15/12/2025
Jefferies
Buy115.00+8.45%110.00Maintain07/11/2025

Mesa Laboratories Inc Earnings Call Summary for Q1/2027

  • Mesa Labs Q1 FY2026 revenue rose 1% to $60.1M, missing estimates of $61.49M by 2.3%; shares flat after hours at $101.62.
  • Gross margin expanded to 64.9% from 62.0% YoY; adjusted operating income jumped 16.5% to $15.0M amid lower costs and efficiency gains.
  • Operating cash flow surged to $14.7M from $1.9M YoY; company reduced debt by $8.7M, targeting net leverage of 1.5-1.75x by FY2027 exit.
  • Sterilization segment fell 3.6% on delivery issues; management frames weakness as execution problem, not demand, with quality standards maintained.
  • Full-year FY2027 guidance deferred to November; next-gen Gyrolab platform launch accelerated to FY2028, BPD expected to grow for full year.
Last Updated: 11/08/2026, 07:26 am
Read Full Transcript

Earnings

Latest Release
10/08/2026
EPS / Forecast
2.68 / 1.88
Revenue / Forecast
60.14M / 61.49M
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.86%
Dividend Yield
0.60%
Industry Median 1.47%
Annualised payout
0.64
Paid quarterly
5-Years Growth
-
Growth Streak

MLAB Income Statement

Compare MLAB to Peers and Sector

Metrics to compare
MLAB
Peers
Sector
Relationship
P/E Ratio
123.6x21.2x−0.4x
PEG Ratio
0.140.030.00
Price/Book
3.1x2.7x2.6x
Price / LTM Sales
2.4x3.0x3.1x
Upside (Analyst Target)
10.8%20.3%47.8%
Fair Value Upside
Unlock10.1%6.2%Unlock

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides sterility assurance testing and laboratory services to the dental and pharmaceutical industries. The Biopharmaceutical Development segment develops, manufactures, sells, and services automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for hereditary disease screenings, pharmacogenetics, oncology related applications, and toxicology research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; and PurePep Symphony and Chorus instruments for peptide synthesis. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as renal care, gas flow, environmental and process monitoring, and torque testing in pharmaceutical, laboratory, medical device, manufacturing, industrial, and environmental applications. This segment’s products include continuous monitoring systems, data loggers, and torque testing systems under the DialyGuard, DryCal, DataTrace, and ViewPoint brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
2.10M37.56%222.88M
Other Institutional Investors
3.65M62.44%386.76M
Public Companies & Retail Investors
0.000.00%0.00
Total
5.75M100.00%609.63M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Long Path Partners, LP8.53%477,12650,594
Long Path Smaller Companies Fund, LP8.53%477,12650,594

People Also Watch

23.000
ISSC
+1.03%
53.39
ITRN
-0.56%
26.820
PPIH
+0.98%
13.610
RFIL
+2.72%
74.440
LQDA
+3.25%

FAQ

What Is the Mesa Labs (MLAB) Stock Price Today?

The Mesa Labs stock price today is 106.04 USD.

What Stock Exchange Does Mesa Labs Trade On?

Mesa Labs is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Mesa Labs?

The stock symbol for Mesa Labs is "MLAB."

Does Mesa Labs Pay Dividends? What’s The Current Dividend Yield?

The Mesa Labs dividend yield is 0.6%.

What Is the Mesa Labs Market Cap?

As of today, Mesa Labs market cap is 633.45M USD.

What Is Mesa Labs's Earnings Per Share (TTM)?

The Mesa Labs EPS (TTM) is 0.86.

When Is the Next Mesa Labs Earnings Date?

Mesa Labs will release its next earnings report on 05/11/2026.

From a Technical Analysis Perspective, Is MLAB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Mesa Labs Stock Split?

Mesa Labs has split 0 times.

How Many Employees Does Mesa Labs Have?

Mesa Labs has 717 employees.

What is the current trading status of Mesa Labs (MLAB)?

As of 15/08/2026, Mesa Labs (MLAB) is trading at a price of 106.04 USD, with a previous close of 113.20 USD. The stock has fluctuated within a day range of 105.24 USD to 115.43 USD, while its 52-week range spans from 58.83 USD to 115.52 USD.

What Is Mesa Labs (MLAB) Price Target According to Analysts?

The average 12-month price target for Mesa Labs is 117.50 USD, with a high estimate of 125 USD and a low estimate of 110 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +10.81% Upside potential.

What Is the MLAB Premarket Price?

MLAB's last pre-market stock price is 127.26 USD. The pre-market share volume is 24.00, and the stock has decreased by 14.06, or 12.42%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.